Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why BioCryst Pharmaceuticals Rose 8% on Thursday

TheMotleyFool

0 0

Why BioCryst Pharmaceuticals Rose 8% on ThursdayPhoto, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png

Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) rose after the company's second-quarter earnings call. A stronger than expected performance from the company's shiny new sales force drove the biotech stock 8.7% higher as of 3:58 p.m EDT on Thursday.

Last December, the FDA approved BioCryst Pharmaceuticals' first drug, an oral treatment for hereditary angioedema (HAE) called Orladeyo. Takeda (NYSE: TAK) already markets a blockbuster injectable treatment for HAE patients and it was expected to pressure BioCryst's first drug launch.

Image source: Getty Images.

Source Fool.com

Like: 0

BCRX

Share